The network aligns research centers with Allucent’s therapeutic Centers of Expertise, covering fields such as oncology, neuroscience, and rare diseases. Unlike traditional models, IGNITE operates on a performance-based framework that mandates rapid feasibility assessments, including a 72-hour response window for sponsors. The program guarantees site activation within 60 days of a final protocol in North America, with a three-to-four-week timeline following regulatory approval in international markets.
In section Releases
Allucent Launches IGNITE Network to Streamline Clinical Trial Delivery
To combat the unpredictability of drug development, Allucent has launched IGNITE, a global network of over 250 pre-qualified clinical research sites. By shifting from ad-hoc site selection to long-term partnerships, the CRO aims to accelerate trial activation and patient enrollment for small and mid-sized biopharma firms.
Patrick Phillips, Allucent’s chief operating officer, noted that the current development environment requires more than basic site access; it demands execution confidence. By fostering mutual accountability between sponsors, CRO teams, and investigators, the network provides access to patient populations totaling more than 50 million individuals. According to Almenia Garvey, the company’s senior director of global feasibility, this early-engagement strategy is designed to keep complex clinical programs on track by identifying potential bottlenecks before they impact trial momentum.
Comments (0)
No comments yet. Be the first!